The agreement to sell B Medical Systems marks a major step forward in simplifying the portfolio to prioritize our core capabilities with the highest strategic impact
The interim efficacy readout, involving around 170 participants with 15-month data, remains on track for the end of March 2026
The Toumai platform, currently the only robotic system with US FDA Study Approval for telesurgery, enabled real-time surgical control with no compromise to patient safety
The study met its primary endpoint with flying colors
INOVIO remains confident in the therapy’s benefits and intends to meet with the FDA to discuss maintaining eligibility under this pathway
Lucid-MS represents a potential breakthrough in the treatment of multiple sclerosis
The drug, currently in a phase 1b/2 clinical trial for small cell lung cancer, is a polymer nanoparticle formulation of SN-38
The company views ESG reporting as a strategic tool to build trust with clients, investors, regulators, and stakeholders worldwide
The cancellation underscores the regulator’s strict stance against misleading cosmetic claims
Subscribe To Our Newsletter & Stay Updated
